Trial · NCT07468526
An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria
NCT07468526, Phase 3, Not yet recruiting, Menzies School of Health Research
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria. Trials, record NCT07468526. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07468526
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria
- NCT number
- NCT07468526
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 1,019 participants, estimated
- Lead sponsor
- Menzies School of Health Research
- Conditions
- Malaria
- Interventions
- High dose ultra short Primaquine, Placebo
- First posted
- 2026-03-12
- Last updated
- 2026-03-12
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence risk of any recurrent vivax parasitaemia within 4 months. | 4 Months | The incidence risk (time to first event) of any recurrent P. vivax parasitaemia within 4 months as determined by microscopy |
| Secondary | The incidence risk of any P. vivax parasitaemia within 6 months. | 6 months | The incidence risk (time to first event) of any P. vivax parasitaemia within 6 months as determined by microscopy |
| Secondary | Incidence of haemoglobin drop >25% to <7g/dl within 14 days of treatment. | 0-14 days | Number of participants experiencing a haemoglobin decrease of \>25% from baseline resulting in Hb\<7g/dl |
| Secondary | Incidence of moderate anaemia within 14 days after starting primaquine | 0-14 days | Number of participants developing haemoglobin \>=5g/dl and \<7g/dl within 14 days after treatment initiation |
| Secondary | Incidence of severe anaemia within 14 days after starting Primaquine | 0-14 days | Number of participants developing haemoglobin \<5g/dl within 14 days of treatment initiation. |
| Secondary | • The proportion of patients requiring blood transfusion within the 6 months follow up period. | 6 months | Participants requiring transfusion due to haemolysis or severe anaemia |
| Secondary | The incidence risk of symptomatic P. vivax parasitaemia within 4 months. | 4 months | The incidence risk (time to first event) of symptomatic P. vivax parasitaemia within 4 months as determined by microscopy. |
| Secondary | Proportion of adverse events within 14 days. | 14 days | The number and proportion of adverse events within 14 days after start of treatment |
| Secondary | The number and proportion of serious adverse events. | 6 Months | The number and proportion of serious adverse events. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07468526
GET https://conductscience.org/api/trials/v1/NCT07468526/registered